Editas Medicine (EDIT) & BAVARIAN NORDIC/S (BVNRY) Critical Analysis

-

Editas Medicine (NASDAQ:EDIT) and BAVARIAN NORDIC/S (OTCMKTS:BVNRY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Risk & Volatility

Editas Medicine has a beta of 3.37, indicating that its share price is 237% more volatile than the S&P 500. Comparatively, BAVARIAN NORDIC/S has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.

Valuation & Earnings

This table compares Editas Medicine and BAVARIAN NORDIC/S’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Editas Medicine $13.73 million 84.70 -$120.32 million ($2.98) -8.18
BAVARIAN NORDIC/S $208.06 million 3.86 $27.54 million $0.29 28.59

BAVARIAN NORDIC/S has higher revenue and earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than BAVARIAN NORDIC/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.2% of Editas Medicine shares are held by institutional investors. 5.2% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Editas Medicine and BAVARIAN NORDIC/S, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine 1 4 6 0 2.45
BAVARIAN NORDIC/S 0 0 0 0 N/A

Editas Medicine presently has a consensus target price of $47.43, indicating a potential upside of 94.46%. Given Editas Medicine’s higher probable upside, equities analysts plainly believe Editas Medicine is more favorable than BAVARIAN NORDIC/S.

Profitability

This table compares Editas Medicine and BAVARIAN NORDIC/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Editas Medicine -623.35% -61.27% -35.09%
BAVARIAN NORDIC/S -18.41% -6.60% -5.23%

Summary

BAVARIAN NORDIC/S beats Editas Medicine on 7 of the 13 factors compared between the two stocks.

Editas Medicine Company Profile

Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

BAVARIAN NORDIC/S Company Profile

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; Biomedical Advanced Research and Development Authority; US Department of Defense; and PCI Biotech. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgård, Denmark.

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.



https://ift.tt/2R8uIG6

Comments

Post a Comment

Popular posts from this blog

Ebola has spread for nearly a year in Congo. Officials are scrambling to ‘reset’ the response. - The Washington Post

-
Image
June 20 at 4:06 PM BUTEMBO, Congo —  A dozen young men revved their motor­cycle engines in front of the wooden gate of a makeshift checkpoint — too impatient to have their temperatures checked or to wash their hands with chlorinated water. Health workers manning the post had little choice but to let them pass. Every day, thousands of people travel this road through the epicenter of Congo’s ongoing Ebola outbreak, where they are supposed to comply with field nurses toting gun-shaped thermometers testing for fevers. But that operation is far from perfect, and extinguishing the nearly year-old outbreak is months away at best. Days with a dozen new cases are normal.  “Ebola is like water. If you don’t build a perfect dam, even a small hole can lead to a flood of new cases,” said Marie Roseline Belizaire, the World Health Organization’s deputy manager for the response.  Health officials are confident the outbreak is not spiraling out of control but are worri...
Read more

TDAP vaccine: When to get it, side effects, and safety

-
Image
c diff outbreak :: Article Creator Fidaxomicin Underused For C Diff Infections, Study Finds CDC / Alissa Eckert Global health organization Unitaid last week called for a "concerted global effort" to introduce accurate and affordable diagnostic tests in low-resource countries to address the rising number of gonorrhea infections and antimicrobial resistance (AMR). In a report released ahead of the United Nations High-Level Meeting on AMR, Unitaid highlights the diagnostic access gaps that results in both undertreatment and overtreatment of gonorrhea infections in low- and middle-income countries (LMICs) with a high burden of gonorrhea. Because of the lack of affordable, rapid point-of-care (POC) diagnostic tests in these settings, treatment decisions are based on observed signs and reported symptoms. Yet more than half of gonorrhea cases are asymptomatic, resulting in a high number of untreated, missed infections. Conversely, lack of gonor...
Read more

HIV Drug Sunlenca (Lenacapavir) Gets FDA Approval - Everyday Health

-
Image
The U.S. Food and Drug Administration (FDA) has approved Sunlenca (lenacapavir), a new type of medication for the most common variant of HIV, HIV-1 (human immunodeficiency virus type 1). Lenacapavir is designed for heavily treatment-experienced adults with multidrug-resistant HIV who are not able to adequately manage the virus with their current treatment regimen. It is an injectable medication administered under the skin (subcutaneously) once every six months. Developed by Gilead Sciences, lenacapavir is the first of a new class of HIV medications called capsid inhibitors, which work by blocking the virus's protein shell (the capsid), thereby interfering with essential steps of the virus's life cycle. In a clinical trial, lenacapavir was able to lower the viral load in patients who were not responding adequately to other therapies. "Today's approval ushers in a new class of antiretroviral drugs that may help patients with HIV who have run out of treatment options,...
Read more